Heda Ventures

Heda Ventures is an early-stage venture capital firm established in 2008 and located in San Jose, California. The firm specializes in investing in disruptive innovations within three primary sectors: biotech, healthcare, and IT technology. Heda Ventures targets seed-stage and early-stage companies, aiming to partner with innovative enterprises that exhibit significant growth potential. The firm is dedicated to supporting entrepreneurs and startups in developing transformative businesses that can create new market opportunities and drive meaningful change in their industries.

Qiang Chen Ph.D

Venture Partner

Haitao Xia Ph.D

Venture Partner

Lin Xie Ph.D

Managing Partner

Hongbin Zheng

General Partner

9 past transactions

Immunowake

Series A in 2022
Immunowake is a biotechnology company specializing in developing new therapies for cancer patients who do not respond to existing immunotherapies. Its focus lies in harnessing the body's immune system to identify and eliminate cancer cells, with a particular emphasis on generating safer and more effective bispecific antibodies through its universal cancer vaccine.

LYNK Pharmaceuticals

Series B in 2021
LYNK Pharmaceuticals is a biotechnology company based in Hangzhou, China, specializing in the development of small molecule drugs aimed at treating tumors and autoimmune diseases. Founded in 2017, the company focuses on the discovery and development of innovative medicines in the fields of oncology, immunology, and inflammatory diseases. Its business operations include new drug research, sales, and activities related to patent authorization and transfer.

Lianchuan Bio

Series B in 2020
Lianchuan Bio is a provider of a genomics and precision medicine platform based in China. The company focuses on the application of genetic technology across various healthcare scenarios. Its platform offers genome sequencing and genetic testing programs, allowing healthcare providers to accurately identify target genes. This capability facilitates significant advancements in clinical gene capture, enhancing the effectiveness of precision medicine.

Citcon

Series B in 2019
Citcon is a payment technology company founded in 2015 that provides a global mobile wallet payments platform for merchants. The company offers a scalable, secure, and open system with a single API that enables merchants to accept domestic and international mobile wallets across web, mobile, and in-store channels. Its platform provides end-to-end payments including processing, gateway services, reporting, and fund settlement, connecting merchants with a network of digital wallets to reach billions of wallet users. Citcon serves tens of thousands of merchants and millions of mobile wallet users worldwide. Headquartered in Silicon Valley, it maintains regional offices in the United States, Canada, Europe, and Asia.

MuMec

Seed Round in 2018
MuMec develops wireless transceiver technologies that significantly reduce operating power for use in Bluetooth low energy and LoRa/Sigfox protocols. Founded in 2014, the company is headquartered in Oakland, California.

Paragon Genomics

Series A in 2017
Paragon Genomics, Inc. is a biotechnology company based in South San Francisco, California, founded in 2015. The company specializes in the development and commercialization of polymerase chain reaction (PCR) reagents and components for molecular biology, focusing on ultra-high multiplex PCR-based target enrichment solutions for next-generation sequencing (NGS). Paragon Genomics offers a range of products, including the CleanPlex targeted library kit and specific panels such as the CleanPlex OncoZoom, BRCA1 & BRCA2, and TP53 Panels, which facilitate the amplification of targeted DNA regions for NGS applications. Their proprietary CleanPlex technology is designed to enhance the accuracy, sensitivity, and cost-effectiveness of targeted sequencing assays, addressing various fields such as oncology, infectious diseases, and genomics-guided research, thereby advancing precision medicine and diagnostics.

Symic Bio

Series B in 2017
Symic Biomedical is a biotechnology company based in San Francisco, California, focusing on developing matrix regulator therapeutics. These therapeutics are designed to target and bind to specific sites within the body's extracellular matrix that have been damaged due to injury or disease. By inhibiting pathological inflammatory responses, Symic Biomedical aims to address conditions such as fibrosis, oncology, and diseases of the central nervous system. The company was incorporated in 2012 and operates as a subsidiary of Symic Holdings, LLC.

ScaleFlux

Venture Round in 2017
ScaleFlux specializes in computational storage solutions, optimizing data center and cloud infrastructure efficiency for various data-intensive applications. Incorporated in 2014, the company is headquartered in San Jose, California with additional locations in China.

Citcon

Seed Round in 2017
Citcon is a payment technology company founded in 2015 that provides a global mobile wallet payments platform for merchants. The company offers a scalable, secure, and open system with a single API that enables merchants to accept domestic and international mobile wallets across web, mobile, and in-store channels. Its platform provides end-to-end payments including processing, gateway services, reporting, and fund settlement, connecting merchants with a network of digital wallets to reach billions of wallet users. Citcon serves tens of thousands of merchants and millions of mobile wallet users worldwide. Headquartered in Silicon Valley, it maintains regional offices in the United States, Canada, Europe, and Asia.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.